Compston A, Coles A. Multiple sclerosis. Lancet 2008, 372: 1502–1517.

Article  CAS  PubMed  Google Scholar 

Kimura K. Regulatory T cells in multiple sclerosis. Clinical & Exp Neuroim 2020, 11: 148–155.

Article  Google Scholar 

Sharief MK, Noori MA, Ciardi M, Cirelli A, Thompson EJ. Increased levels of circulating ICAM-1 in serum and cerebrospinal fluid of patients with active multiple sclerosis. Correlation with TNF-α and blood-brain barrier damage. J Neuroimmunol 1993, 43(1–2): 15–21. https://doi.org/10.1016/0165-5728(93)90070-F.

Article  CAS  PubMed  Google Scholar 

Nishihara H, Perriot S, Gastfriend BD, Steinfort M, Cibien C, Soldati S. Intrinsic blood-brain barrier dysfunction contributes to multiple sclerosis pathogenesis. Brain 2022, 145: 4334–4348.

Article  PubMed  PubMed Central  Google Scholar 

Schreiner TG, Romanescu C, Popescu BO. The blood-brain barrier-a key player in multiple sclerosis disease mechanisms. Biomolecules 2022, 12: 538.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, et al. Fingolimod (FTY720): Discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010, 9: 883–897.

Article  CAS  PubMed  Google Scholar 

Aly L, Hemmer B, Korn T. From leflunomide to teriflunomide: Drug development and immunosuppressive oral drugs in the treatment of multiple sclerosis. Curr Neuropharmacol 2017, 15: 874–891.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reich DS, Arnold DL, Vermersch P, Bar-Or A, Fox RJ, Matta A, et al. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: A phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2021, 20: 729–738.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wolf SD, Dittel BN, Hardardottir F, Janeway CA Jr. Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J Exp Med 1996, 184: 2271–2278.

Article  CAS  PubMed  PubMed Central  Google Scholar 

O’Connor RA, Prendergast CT, Sabatos CA, Lau CWZ, Leech MD, Wraith DC, et al. Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis. J Immunol 2008, 181: 3750–3754.

Article  PubMed  Google Scholar 

Fletcher JM, Lalor SJ, Sweeney CM, Tubridy N, Mills KG. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol 2010, 162: 1–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Z, Korhonen EA, Merlini A, Strauss J, Wihuri E, Nurmi H, et al. Angiopoietin-2 blockade ameliorates autoimmune neuroinflammation by inhibiting leukocyte recruitment into the CNS. J Clin Invest 2020, 130: 1977–1990.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang H, Zhang F, Yang J, Han S. Angiopoietin-1 ameliorates inflammation-induced vascular leakage and improves functional impairment in a rat model of acute experimental autoimmune encephalomyelitis. Exp Neurol 2014, 261: 245–257.

Article  CAS  PubMed  Google Scholar 

Bennett J, Basivireddy J, Kollar A, Biron KE, Reickmann P, Jefferies WA, et al. Blood-brain barrier disruption and enhanced vascular permeability in the multiple sclerosis model EAE. J Neuroimmunol 2010, 229: 180–191.

Article  CAS  PubMed  Google Scholar 

Paudel YN, Angelopoulou E, Bhuvan CK, Piperi C, Othman I. High mobility group box 1 (HMGB1) protein in multiple sclerosis (MS): mechanisms and therapeutic potential. Life Sci 2019, 238: 116924.

Article  CAS  PubMed  Google Scholar 

Bucova M, Majernikova B, Durmanova V, Cudrakova D, Gmitterova K, Lisa I, et al. HMGB1 as a potential new marker of disease activity in patients with multiple sclerosis. Neurol Sci 2020, 41: 599–604.

Article  PubMed  Google Scholar 

Chen R, Kang R, Tang D. The mechanism of HMGB1 secretion and release. Exp Mol Med 2022, 54: 91–102.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Harris HE, Andersson U, Pisetsky DS. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol 2012, 8: 195–202.

Article  CAS  PubMed  Google Scholar 

Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ, et al. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 2006, 26: 174–179.

Article  CAS  PubMed  Google Scholar 

Magna M, Pisetsky DS. The role of HMGB1 in the pathogenesis of inflammatory and autoimmune diseases. Mol Med 2014, 20: 138–146.

Article  PubMed  PubMed Central  Google Scholar 

Ren W, Zhao L, Sun Y, Wang X, Shi X. HMGB1 and toll-like receptors: Potential therapeutic targets in autoimmune diseases. Mol Med 2023, 29: 117.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Malhotra S, Fissolo N, Tintoré M, Wing AC, Castilló J, Vidal-Jordana A, et al. Role of high mobility group box protein 1 (HMGB1) in peripheral blood from patients with multiple sclerosis. J Neuroinflammation 2015, 12: 48.

Article  PubMed  PubMed Central  Google Scholar 

Robinson AP, Caldis MW, Harp CT, Goings GE, Miller SD. High-mobility group box 1 protein (HMGB1) neutralization ameliorates experimental autoimmune encephalomyelitis. J Autoimmun 2013, 43: 32–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mo J, Hu J, Cheng X. The role of high mobility group box 1 in neuroinflammatory related diseases. Biomed Pharmacother 2023, 161: 114541.

Article  CAS  PubMed  Google Scholar 

Shi J, Xiao Y, Zhang N, Jiao M, Tang X, Dai C, et al. HMGB1 from astrocytes promotes EAE by influencing the immune cell infiltration-associated functions of BMECs in mice. Neurosci Bull 2022, 38: 1303–1314.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun Y, Chen H, Dai J, Zou H, Gao M, Wu H, et al. HMGB1 expression patterns during the progression of experimental autoimmune encephalomyelitis. J Neuroimmunol 2015, 280: 29–35.

Article  CAS  PubMed  Google Scholar 

Sun Y, Chen H, Dai J, Wan Z, Xiong P, Xu Y, et al. Glycyrrhizin protects mice against experimental autoimmune encephalomyelitis by inhibiting high-mobility group box 1 (HMGB1) expression and neuronal HMGB1 release. Front Immunol 2018, 9: 1518.

Article  PubMed  PubMed Central  Google Scholar 

Elbaz B, Popko B. Molecular control of oligodendrocyte development. Trends Neurosci 2019, 42: 263–277.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kuhn S, Gritti L, Crooks D, Dombrowski Y. Oligodendrocytes in development, myelin generation and beyond. Cells 2019, 8: 1424.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Harrington EP, Bergles DE, Calabresi PA. Immune cell modulation of oligodendrocyte lineage cells. Neurosci Lett 2020, 715: 134601.